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Chapter 45 
Portasystemic Shunting for 
Metabolic Disease 
THOMAS E. ST A RZL 
JOSEPH BENICHOU 
For many years portal venous diversion has 
been used for the haemodynamicobjectives of 
stopping or preventing' haemorrhage from 
oesophageaf varices or, less commonly, to treat 
intractable ascites. Since 1963, a new dimension 
has been added to the old operation of 
portacaval shunt by employing this procedure 
to alter favourably the course of patients with 
two inborn errors of metabolism. glycogen 
storage disease and hyperlipoproteinaemia. In 
this chapter we will discuss the results and the 
pl*:ntiai l'l),lUP,'!dliYe risb of portal di\cr:::.ioll 
for these nC\1 mdi<.:ati\'m. as \\ell as the pl)ssibk 
roec~~nisms of benefit. 
GL YCOGEN STORAGE DISEASE 
Portal diversion was first performed for 
glycogen storage disease almost 14 years ago,34 
Then the rationale for the procedure was naive 
by today's standards. It was hoped that by 
short-circuiting splanchnic venous blood 
around the liver, glucose would be made more 
readily available to peripheral tissues with relief 
of hypoglycaemia. and that the liver would be 
coincidental!~ d:g!:cl)genated. As will be 
discussed 1<1 ter. it has since been lea rned fn'lll 
animal experimentati,.n that the consequl.'llces 
of portacaval shunt are far more subtle and 
wide-ranging than that simple \·ie",·. 
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That first patient. who had Type III glycogen 
storage disease, is still alive almost 14 years after 
portacaval transposition. The by-passed portal 
venous blood is replaced with blood returning 
from the inferior vena cava with this operation. 
which was first.described in animals by Child et 
al 6 (Figure 45.1). The transposition was used in 
order to avoid the potential hazards of Ed. 
fistula. It was appreciated then and ampI\ 
confirmed since 24 that most animals. including 
subhuman primates. develop wasting and 
encephalclpath:, afln portal diyer~iollK b~:: 
was not ap!'reciated that human, \\'l)ldd he' .:' 
exception to this generalization. 
Our first patient had a remarkably un· 
troubled convalescence and was discharged 
from the hospital nine days postoperati\ ~h 
Before and after operation, there were ele .. a· 
tions in the transaminases which a decade later 
were still slightly increased. She had u 
splenectomy 43 months after transposition for 
thrombocytopenia at which time the portacu\al 
anastomosis draining the splanchnic bed wa, 
proved to be open. There has been no evidc!1l"l' 
of portal hypertension. indicating tha t t lil' 
portacaval anastomosis draining the splanchniC 
bed is still open. An inferior vena C3\',lgLII11 
almost 10 years postoperatiYely revealed fill" \'\ 
s\stemic 'enOllS hlood fWIll the di,tal \ ell.! L 
t~F the liver but with a maj0r by·pass arl11lIhll .. 
1I\'er thwu!!h ,\7\ '-'l'lIS and hCl1lia/\ el)lI' , 
laterals (Figure 45.2). The degree of a-z;gl)lI' b., 
passing was similar to that obsened \\ ;,1, 
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comparable angiographic study more than nine 
years earlier when the patient was three-months 
postoperative. 
A patient similarly treated by Riddell et al2s 
in Bristol. England. also survived for a long 
time. Ridde)]'s patient mo\'ed to Canada and 
was temporarily lost to follow-up. Eventually he 
'" a~ traced through the Immigration Depart-
ment. Angiographil: studies were carried out in 
Calgl;U'y'! __ Alberta, in December 1971, and 
confirmed by us in January 1973. The vena cava 
was obstructed (Figure 45.3, left), a com-
plication which had probably occurred a long 
time previously since collateral venous channels 
were highly developed and lower limb oedema 
was minimal. The anastomosis draining the 
splanchnic venous bed was shown to be open 
(Figure 45.3, right). 
One more portacaval transposition was 
performed. The attempt cost the life of our 
second patient. when the liver was unable to 
transmit the rerouted vena caval flow, causing 
hepatic swelling and uncontrollable acidosis. 
This seven-vear-old child died two da\'s later. 
te~- and Hermann and Mercer l ... subs~quently 
recommended that the simpler procedure of 
portacaval shunt be used. To our knowledge 
this approach has been followed in all later 
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Figure 45.1. The operation of portacaval 
transposition that was used for the first 
two patients with glycogen storage disease 
who were treated with portal diversion. 
Note that the central portal vein is 
revascularized with vena caval blood. 
From Starzl et al,34 with the kind 
permission of the editor of Surgery. 
cases. By the spring of 197335 our own series of 
patients had reached seven, and six more had 
been formally reported in the literature from 
other centres. Since then our cases have 
increased to 10 and it is upon this personal 
experience (Table 45.1) that most of the 
opinions in this report will he hased. We ha\'e 
had no operati\e deaths or techmcal failures 
after end-to-side ponaca\al shunt. 
Our original patient with transposition is still 
living after 14 years, as are seven of the eight 
patients treated with simple portacaval shunts. 
These last seven patients now have follow-ups of 
one to 5! years (mean 50 months). The ages of 
all of 9ur 10 patients, types of ~isease and 
symptoms are summarized in Table 45.1. Type I 
disease (glucose-6-phosphatase deficiency) has 
been the most common indication for treat-
ment, with Type III disease (amylo-I,6-
glucosidase deficiency) being a distant second. 
. Metabolic effects 
After portal diversion. most of the children who 
had pre-existing hypoglycaemia did not have 
relief of this problem or the relief was not 
complete. Thus. night feedings usually had to be 
:1, 
• I 
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Figure 45.2. Inferior vena cavagram In March 1973. 91 years postoperatively in Colorado Case I showing a paten! 
cava l-portal anastomosis (arrow) under two conditions of dye injection . Significant flow through the liver. as well as around II 
by t he azygous and other colla terals. was well seen at fl uoroscopy . IVC - distal inferior vena cava; LR V - left renal vein : P\' 
portal vein. From Starzl et ai, J' with the kind permission of the editor of Annals of Surgery. 
Figure 45.3. Studies of the Bristol case of portacaval transposition . The original operation was on 5 May 1965. and fr ~ 
examination depicted. which was in December 1971 , was performed by Dr R.J . Sommen'ille at the Foothills eo>ril ~ : 
Calgary. Alberta . (Left) Inferior vena ca\agram show ing obstruction at the anastomotic site (arrow). I\'C - dlqai ink!! 
\(' n;!. CJ.\'J : LR\' - left frnJI \('in D~DtED h~ C'\; l ell :- l\ e yK:l_Dlf~~teit1:-KK q:J the :Kl?y~D-D llD ::-Ky · ~ fEDm K (R leht) a:: m~yn ... ;r.lIh'r. . \:; : ' , 
portac~yD al anastomosis (arrow) b\' mean:' of ~ retrograde cathete rizJtion , n:e · rroyinl~i infe;ior y Den~ L'a\ J: P\' - PI"t ,'-' .,' ' 
From pt~rz i et al. ,< with the kind pcrm l" ic'n or the editor "I' ~lfl1ulKy .,: pllr~f Dn K 
Joseph Benichou 
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Table 45. \. Palierl/s l\'ill1 Glyco[.!en Slorage' Disease Trealed by Porlal DiI-ersion al Ihe Unil'('fsily of Colorado. 
Glycogen Symptoms preoperatively 
Case storage Date of Persistent Survival 
No. Age disease operation Hypo. Growth hypoglycaemia post-shunt 
type glycaemia Acidosis retardation postoperatively 
la S III 10.15.63 x x x No Alive 14 years 
2" 7 I 6.26.68 x x x Died 2 days 
3 7 I 5.2.72 x x X Yes' Alive 5 year, 
4 II I 5.17.72 x x x No Died 41 yea rs 
5 10 VI R.2.72 x Alive 4l years 
6 5 III 11.7.72 x x x No Alive 4~ year~ 
7 3 III 11.8.72 x x x Ye, Alive 41 years 
8 8 I 8.13.73 x x x Yesh Alive 31 years 9 12 I 12.14.73 x x x Yes" Alive 32 years 
10 I I 9.2.76 x x x Yes Alive 8 months 
• Operation was portacaval transposition. The last eight patients had simple portacaval shunt. 
h Overnight feeding via nasogastric tube started 2) to 4 years after porta<;aval shunt. 
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figure 4~K4K Plasma in'ulm and "Iu,'ose c"ni~ntrgtiIDnK 
bd'.'re and ai"lcr p"na,'a\dl ,hunt In- a child IEDaIe~K T.lhle 
45,1) with Type I gl}cogen storage disease. Oral glucose 
tolerance test. 
continued. Studies of plasma insulin and 
glucagon in several of these patients have 
revealed changes (Figure 45.4). The flat 
peripheral insulin curyes typical of Type I 
glycogendisease22 became significilntly ele-
vated after portacaval shunt, :and there were 
smaller increases in glucagon. The glucose 
tolerance curves were a little different before 
and after operation. 
Liver glycogen concentrations in all the 
patienfs later biopsied were not changed. In 
spite of this. the liver size in several of our 
patients and those reported by others underwent 
a yer~ ob\il1l1s reduction :.is mca;;u!'cJ with ]j\er 
scan planimctry. [\en if ob\illU' ~hrinkage did 
not occur, postoperative biopsies always 
showed a diminution in individual hepatocyte 
size similar to that produced in animals 
by portacaval shunt. 35 
In contrast to the incomplete relief of 
hypoglycaemia, all components of the hyper-
lipidaemia which is a characteristic of the Type I 
disease had profound and permanent relief 
(Figure 45.5), as was first obsc;rved by Hermann 
and Mercer' 6 and confirmed by Folkman et al 12 
and in our own cases. 35 Correction of other 
metabolic defects was observed, including 
abnormal bleeding, uric aci<;i elevations and 
abnormal calcium metabolism. 35 
G /'(Il\' I II 
All 10 of our patients had growth retardation 
before portacaval shunt. Afterwards. height 
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Figure 45.5. Effect of parenteral hyperalimentation and end-to-side portacaval shunt on the plasma lipids of Patient 4 who~ 
diagnosis was Type I glycogen storage disease. Note the rapid and relatively complete reversal of all abnormalities. Frorr. 
Starzl et al,35 with the kind pennission of the editor of Annals of Surgery. 
increases, which in most cases had virtually 
ceased. have occurred at the rates listed in Table 
45.2, that is, approximately 0.5 cm per month .. 
Quantitative measures oC growth were 
obtained with -radiographic techniques. 35 An 
example of the results is shown in Figure 45.6. 
Comparison of the wrist and hands in this 
seven-year-old stunted child before and II! 
months after operation showed the phenomenal 
effects of bone age doubling. In addition to the 
size change. mineralization occurred. as did the 
appearance of new wrist bones. Circulating 
somatotrophin in t~ese patients was normal. 
The growth spurts may have been at least 
partially attributable to the: increased insulin 
distribution to -the periphery mentioned earlier 
(see Figure 45.4) since, in recent years, insulin 
has been recognized to be a major growth 
hormone comparable in potency to soma to-
trophin. The simpler possibility that better 
nutrition was responsible must also be con· 
sidered. 
Fij!ure 45.6. The dramatic wrist and hand bone growth ..Ind mineralization in Case:< In the fir>! J I i postoperJ::'.c:;-:. ~K::K I' 
bracket on the left index finger is 5 em in length. From Starzl et al,B with the kind pennission of the editor of Annal, (.' 
Surgery. 
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Table 45.2. Growl}, Rail' and Complicalions Following Por/al 
Diversion Jar Glycogen Siorage Disease. 
Growth rate 
Case (em/month over Complications 
No. 9 to 120 months) 
I 0.49 
2 Op. Death 
3 0.50 Macroadenomatosis 
4 E1K~U Died 4~ years post-shunt. 
Primary pulmonary hypertension. 
NH., = 85 ~gfll ml; 
macroadenomatosis 
5 0.53 Renal artery stenosis 
surgically corrected 
32 months post-shunt 
6 0.62 
7 0.50 
8 0.49 
9 0.88 Renal stone two months post-
shunt. Mild arterial hyper-
tension; macroadenomatosis 
IO 0.22 
Mean 0.47 
Encephalopathy and other risks 
None of our patients has developed hepatic 
encephalopathy_ The highest blood ammonia 
recorded was 49.3 pmol/l (84 pg/per cent) in a 
child who died almost five years after portacaval 
shunt during an attempt at transcaval radio-
graphic visualization of the portacaval anas-
tomosis. This patient (Case 4) had not achieved 
the full expected growth after operation (Table 
-+~K~ I. had mild systemic hypertension. and had 
unexplained trJI1sient hElut~ of cyanosis. h:per-
\enllldtlL)n and UI1C·L'I1SCJOusness. Except for the 
slightlY.elevated blood ammonia, liver function 
was normal. 
At autopsy, the liver had macro-
adenomatosis. Very minor protoplasmic astro-
cytosis was present in the brain. A finding that 
had not been suspected during life was advanced 
right ventricular hypertrophy and dilatation. 
The smaller pulmonary arteries -and arterioles 
had medial muscle hypertrophy, medial and 
intimal fibrosis_ scattered fibrinoid necrosis and 
numerous plexiform lesions. In retrospect, the 
patient died from a cardiopulmonary compli-
cation of the kind that has been documented in 
patients with Type I glycogen storage disease or 
other liwr disease. 21 
This complication has been termed '\asocon-
strictive piilmonar~ hypertension'. It has been 
speculated that a humoral vasoconstrictive 
agent, which normally is completely detoxified 
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by the liver. is responsible for the hypertrophic 
lesions in the pulmonary vasculature. It is con-
ceivable, although unlikely, that the develop-
ment of a renal artery stenosis in Patient 
No.5 (Table 45.2) could have been caused by 
the same mechanism. 
Three of our 10 patients developed the 
hepatic lesions which have been termed both 
macroadenomatosis and nodular hyperplasia. 
Filling defects were noted by liver scan with 
some waxing and waning of size. This 
complication is common in patients with Type I 
glycogen storage disease, particularly with 
advancing age, and was recently reported in 
seven of eight patients who were three to 28 
years 01d. 18 
The value of enteral or parenteral feeding 
Seven years ago, Folkman et al 12 of Boston 
Children's Hospital added an important thera-
peutic dimension by showing how preoperative 
parenteral hyperalimentation would reduce the 
risk of portacaval shunt by normalizing pre-
existing hepatomegaly, acidosis and other 
abnormalities, including hyperlipidaemia. The 
Harvard group as well as the Vanderbilt 
team 3 • 14 have greatly extended these original 
observations. 
Greene et al,14 for example, showed that 
continuous night feeding through a gastrostomy 
or gastric tube resulted in many of the same 
benefits as the parenteral hyperalimentation or 
as the portacaval shunt. Apparently, the night 
feeding was 0riginalh tried to contrul the 
nocturnal hypoglycaemia v.hich. a~ mentlOned 
eJrlier. \\a s not rehe\ ed by portal di\ersion. It 
was soon observed that the night feedings 
contributed to, or were primarily responsible 
for. the same kinds of growth spurts and relief 
of metabolic abnormalities (including hyper-
lipidaemia) which are ameliorated by portacaval 
shunt. Greene et al 14 have- shown that systemic 
plasma insulin levels are more than doubled by 
such treatment and that glucagon is decreased, 
leading them to speculate that' the hormone 
changes were responsible for the benefits. 
Whatever the explanation, this kind of treat-
ment is an alternative to portal diyersion as the 
primary treatment of children with glycogen 
storage disease. and even after portacaval shunt 
it has an additicma I val ue as ha~ been evident in 
three of our patients (T a bIe -l).l) who had 
hypoglycaemia. retardation of growth. or both . 
Glucose and amino acid mixtures have both 
been effective for the gastric feeding. 
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HYPERLIPIDAEMIA 
The observations about lipid lowering after 
portacaval shunt in patients with Type I 
glycogen storage disease (see Figure 45.5) were 
responsible for our suggesting the same 
operation to treat hyperlipidaemia. 31 It has 
been 4! years since a completely diverting 
portacaval shunt was first performed clinically 
for the purpose of lowering the serum 
concentration of cholesterol and low density 
lipoproteins (LDL). Since then, we have treated 
two more patients by this method. As of May 
1977, an additional nine patients had the same 
procedure in other centres and were docu-
mented in the literature. 8 . 11.20.26.36.37 
These 12 cases represent less than half of the 
true total. Through an informal registry that has 
been kept at the National Institutes of Health, 
Bethesda, U.S.A., it is known that more than 30 
portacaval shunts have been carried out for the 
treatment of hyperlipidaemia with results that 
are in general agreement with the smaller 
sample which is accessible through the formal 
literature and upon which we will comment in 
this chapter. All three of our patients had 
homozygous Type II ]1yperlipidaemia. 
In Type II hyperlipidaemia, Goldstein and 
Brown 13 have suggested that there may be an 
absence of or defect in the cell surface receptor 
sites which normally bind and transport LDL 
cholesterol into the cell. Because chole~terol 
does not enter the cell, they proposed that there 
is an absence of the normal feedback sup-
pressi":i e,f chLllestcrol syntbesi~K 
The hc'ntozygc1us form of Type II h:- I'er-
Iipoprotemaemia has a ~hockingly poor prog-
nosis· if, as is usually the case, there is not a 
good response to medical therapy. Lipid-rich 
deposits are laid down in widely separated 
superficial and deep parts of the body, including 
biood vessels where premature atherosclerosis is 
the consequence. Cardiac valves are similarly 
affected, with aortic stenosis being particularly 
common. The patients usually die of cardio-
vascular complications before the age of 20 
years despite all conventional therapy. The 
gravity of the situation seemed to justify the trial 
of a new approach. 
Coluradu cases 
Our first patient, an ll-year-old girl. had 
suffered a major myocardial infarction about 
Thomas E. Star=! & Joseph Benicholl 
two months before the portacaval shunt. After 
the portal diversion, her serum cholesterol 
values fell from about 20 mmol/I (800 mg/dl) to 
levels that were consistently below 10 mmol,'1 
(400 mg/dl) (Figure 45.7). Unsightly xanthomas 
began to 'resorb from visible subcutaneous and 
tendinous locations (Figure 45.8). Attacks of 
pre-existing angina pectoris became less fre-
quent and finally stopped. By cardiac catheteri-
zation 16 months after the end-to-side porta· 
caval shunt was performed, there was good 
evidence that reversal of aortic stenosis had 
occurred, with a diminution of the aortic valve 
gradient from 7.45 to 1.33 kPa (56 to 
10 mmHg).28 The coronary arteries were also 
thought to be less diseased than before. 
although three stenoses were still present. More 
than 11 years after portacaval shunt, the girl 
died suddenly while coming home from school. 
At autopsy, the residual coronary arten 
disease was confirmed. There was a larg~ 
ventricular aneurysm. The conclusion was that 
death was probably caused by an acute cardiac 
arrhythmia. 33 She should have been submitted 
to a coronary revascularization procedure as 
wa.s done in Case 2 (see below). The decision 
-against this was taken with the hope that the 
coronary artery stenoses would regress 
spontaneously .. 
The portacaval shunt was widely patent. The 
liver, which weighed 618 g, was grossly normaL 
and microscopically it was unchanged from the 
biopsy specimen that was obtained six months 
postoperatively. On light and electron mich'-
scopy. the most prominent finding~ \\C-,' 
shrinkage of tbe' hepat~FEDF te sileo Jerk!h'; 
rough endoplasmic reticulum. and the aCl'ur: .. 
lation of intracytoplasmic lipid deposits. qhe~e 
changes are typical of those caused in the liver 
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I , 
by portacaval shunt in all species studied so 
far. 24 Hepatic function had not been changed 
by portacaval shunt as judged by standard liver 
function tests. 
We have perfonned a portacaval shunt on 
two more patients with the same diagnosis 
(elses ~ and i. q~l bl e -1R I ~ F Pa tIent '-:0 . ~ \\<lS a 
se\en-year-old girl a t the time of oreration. She 
had rreorerat I \ e serum c ho lesterol \'al ues that 
averaged 25,82 ± 1,22 (s .d ,) mmol!] (997 ± 47 
[s,d.] mglOO mn \\hile she was on a \ery low 
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(a) 
Figure 45.8. The hands of Patient I of the 
hyperlipidaemia series two weeks before 
(a) and 16 months after (b) portacaval 
shunt. 
(b) 
cholesterol diet. Six months arter the shunt, the 
cholesterol level measured in the same labora-
tory was 15.54 mmolll (600 mg/ IOO ml) (a 40 
per cent reduction). despite a relaxat ion of the 
diet. These values have continued to fall under 
careful medical management bv Dr Da\'id 
Bilhc'im er o f So uthwestern LnI\erslt y Medical 
Center. The cholesterol concentrati o ns during 
the last year ha\e been 11.66 ~ 1. 7:\ mm o l. 1 
(450 ± 67 mg per cent). The xanthomas on her 
heels. elbows and hands either ha\'e reso rbed 
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Table 45.3. Patients with Typ£' II Hyperlipid(}cmia Treated at the Unil'enit.l' o.fColorado. 
Serum cholesterol 
mmol!! (mglOO ml) 
Case Age Date of Clinical Comments 
No. operation Pre-shunt Post-shunt Final ~~ result 
reduction 
12 3,1.73 19.92(769) 7.51(290) 
2 7 10.4.74 25.82(997) 11.66(450) 
3 8 8.5.75 25.90(1000) 15.54(600) 
completely or have greatly diminished in size. 
This child also had aortic stenosis and angina 
pectoris. Because of persistence of her cardiac 
disease. she was treated with aortic and mitral 
valve replacement plus double coronary artery 
by~pass two years after portacaval shunt. The 
operation was carried out by Dr Robert 
McGehee and his associates at the Fort Worth 
Children's Hospital. The patient has returned to 
school with essentially unlimited activities. 
Dr Bilheimer has written us: 'Our therapeutic 
approach continues to be one of trying to get 
Mary's cholesterol as low as possible with 
medication. I am lotally cominced that the 
rNtac;l\al shunt yya~ tremendously helrful to 
her I d(luhllhal \\c' \\,',uIJ h~jye rr\ll'ceded \\ilh 
the cardiaC: surgery If ncr choicqerul were still 
,-in the 23 to 25 mmoll (900 to 1000 mg per 
cent) range. Her present cardiac difficulties are 
an extension of those already present before the 
shunt surgery. Our main job now is to try and 
retard the development of atherosclerosis in her 
coronary by-pass grafts: 
A third patient had a portacaval shunt 
performed 24 months ago. The child was from 
France and has been managed through a 
collaborative effort with Professor Jean Rey 
and Dr J. Schmitz of the Hopital des Enfants 
Malades and Professor J.-L deGennes of the 
H6pitaux de Paris (Clinique Endocrinologique 
de la Pitie). The patient was eight years old at 
the time of operation (In ~ August 1975. 
Preoperati\ely. t~ pical xdnthofl1a~ were pro-
minent on the feet. knees. elhows. huttocks and 
popliteal fossa. The serum cholesterol con-
centration averaged 25.90 mmol;1 (1000 mg per 
cent) with wry little \ariation despite a low 
62 Died 18\ Old myocardial infarct with 
months; ventricular aneurysm: residual 
cardiac stenoses of coronary art~fleIK 
arrest xanthomas had disappeared 
55 GQod Had aortic and mitral valve 
replacement plus double coronar~ 
artery by-pass 25 months after 
shunt: xanthomas nearly 
completely disappeared 
40 Good Xanthomas slowly disappearing 
cholestero~ diet and maximal treatment with 
cholestvramine. nicotinic acid and clofibrate. 
Skin ~ulture results I J were diagnostic of 
homozygous Type II hyperlipidaemia. Aortic 
angiography in April 1975 showed se\'erc 
atheromatous disease of the aorta with supra-
aortic narrowing. The coronary. mesenteric and 
renal arteries were patent. There was mild aortic 
insufficiency. 
After portal diversion the serum cholesterol 
value fell to 14.3 to 16.8 mmol/I (550 to 
650 mg per cent) (40 per cent fall). The visihle 
xanthomas slowly resorbed. The patient was 
asymptomatic before operation and remained 
so afterwards \\ith good grO\\Ir. and dc" .:1. ' . 
men!. Hi, \1 l'rkmg e!ectrocard:c,;!,'Jm '.. 
normal to June 197 7 , At that tIme. n16enk:i, 
arteriography was performed at the Hopital de' 
la Pitie.in Paris. Late phase venography showed 
the portacaval shunt to be patent. 
The patient was seen in Demer during the' 
first week of August 1977. The cholesterol 
concentrations ranged from 15 to 16 mmol I 
(580 to 616 mg per cent). Liver function tesb 
were normal except for a blood ammonia of 
93 Ilmol!1 (I58 J.lg per cent) (normal less than 
35 Ilmol!1 [less than 60 J.lg per cent]). 
Changes in peripheral insulin and glucag\">n 
content in two of our three patients haw hee:, 
noted. Preoperative values were normal. Po,,:· 
operatively, systemic venous insulin and glue.:-
gon values \\'ere b(lth increased. especi:!l!'. t ' 
former (Figure .+5.9). 
'\one of our three patients \Iilh h;'. 
Iipidaemia has had any signs of hcl'-':' 
encephalopathy. although one (Patient 3) h~l~ ::" 
elevated blood ammonia value. '\ewrthe:c'· 
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Figure 45.9. Systemic venous plasma glucose, insulin and glucagoq concentrations in Patient 2 with hyJ'Crlipidaemia before 
and after portacaval shunt. Oral glucose tolerance test. 
the use of portacaval shunt to ameliorate 
hyperlipidaemia a~pts a trade-off of sub-
optimal conditions of liyer perfusion in return 
for metabolic improvements (see 'Mechanism of 
Portal Diversion Effects', below). Realization of 
this fact has prompted us to recommend 
portacaval shunt for this inborn error only if the 
patient was homozygous. However. the freedom 
from encephalopathy in our cases suggests that 
symptomatic heter07\gotes who are fefractor\ 
to medical lileLtr: ,h"L1Id ~!1"I he lDlDnDgEi~cI; l,)r 
portal d;\er,i,"r, The }'dlle111 "f yy·ED~lieyKKK1 c'; 
probably had the helerozygEFr~ trait. 
Oilier reporls 
In the nine cases reported in the literature by 
others,8. 11.20.2,6.36.37 the decreases in serum 
cholesterol have been variable from patient to 
patient, as in our three cases. A significant fall 
was usually obtained if the shunt was patent. 
Cardiac symptoms were often relieved and 
resorption of xanthomas proceeded even if the 
falls in serum cholesterol concentration were 
not great. The latter finding has raised the 
possibilit~ that cholesterol depL1ts ma~ keel" the 
serum cholesterol concentrations high until the 
rese1rption i~ nearly complete. Failure to ob~en~ 
an antilipidaemic effect has been associated with 
thrombosis of the shunt. 8. 11 
Weglicki et aP- have used portacaval shunt 
and' coronary artery by'-pass together in a young 
patient - suffering from premature athero-
sclerosis. This kind of combined therapy will 
probably be used more frequently in the future, 
as was illustrated also by the management of 
our Patient 2. 
'IECHA'IS'. OF PORTAL DI\'[I{SIO,-
EFFECTS 
It has been increasingly appreciated during the 
last decade that venous blood from the 
splanchnic viscera has liver-supporting qualities 
not found to the same degree in other kinds of 
arterial or venous blood, 29: 30.32 The so-called 
hepatotrophic effects of portal blood have been 
noted under several experimental conditions to 
include hypertrophy, glycogen storage, hyper-
plasia and increase of several synthetic func-
tions. The main splanchnic venous hepato-
trophic factors are almost certainly endogenous 
hormones of which the single most important 
seems to be insulin. The high concentrations of 
nutrients from the intestine probahly pla~ a 
sigOificant contributory role. 
With portaca\al shunt theSe humoral and 
non-humoral portal factors are lost to the liver 
on first pass. Subtle but fundamental changes in 
1058 
hepatocyte structure and function result. As 
suggested earlier, changes in the hormone 
environment of the liver and the rest ofthe body 
caused by portacaval shunt could explain the 
palliation of patients with glycogen storage 
disease. 
The loss of portal hepatotrophic factors may 
also explain the amelioration of hyper-
lipidaemia. The antilipidaemic effect of porta-
caval shunt can be demonstrated with a normal 
starting level of serum cholesterol just as easily 
as with a pathologically high concentration. 
This was first observed by Winter et al 38 in 
normal dogs and confirmed in that species by 
US32 and by others. 7 • 15 .1" The same has been 
seen in rats, I o. 23 pigs4 • 5 and baboons.29 
Our studies in the dog 29 and investigations in 
the rat, 19. 23 pig4 • 5 and human2 have shown or 
suggested that a reduction in hepatic cholesterol 
and/or LDL synthesis is responsible, at least in 
part, for the cholesterol falls. Only the report of 
Coyle et al in dogs has denied this. 7 lther~ 
factors may contribute to the antilipidaemic 
effect of portal diversion as Ahrens and we have 
speculated. 1.29 
Our experiments in dogs have suggested that 
the main reason for decreased hepatic choles-' 
terol synthesis is deprivation in the liver of 
insulin. 29 One consequence is a mooerately 
severe liver injury of the kind described earlier in 
the autopsy findings of Patient 2. 
Eaton9 has recently proposed that the 
changes in glucagon metabolism may be 
important in the antilipidaemic effect of portal 
diversion. Further clarification of these 
me-chanisms \\ill he importanl if treatment 
KilternKlllye~ It' r',-,ndCl\a! ~hunt are It' he 
e\ ohd. 
Sl'MMARY 
Complete portacaval shunt was used to treat 10 
patients with glycogen storage disease. A 
favourable effect was noted on body growth and 
a number of metabolic abnormalities. More 
recently. continuous night feedings with an 
intermittently-placed gastric tube or through a 
gastrostomy has been shown to be helpful either 
before or after portacaval shunts. Such alimen-
tation techniques may eliminate the need for 
~hunts in some r.ttients and be of adjll\ant 
benefit in others. 
Three patients with homozygous Type II 
hyperJipidaemia were submitted to complete 
Thomas E. Starzl & Joseph Benichou 
portacaval shunt. There was a substantial fall in 
serum cholesterol in each case, resorption of 
xanthomatous deposits on the skin and tendons, 
and possibly a partial reversal of some 
cardiovascular complications. One patient died, 
18 months after portacaval shunt, apparently 
from a cardiac arrhythmia. The other two 
patients are in good health, one after subsequent 
double heart valve replacement and double 
coronary artery by-pass. Portal diversion seems 
capable of markedly altering the outlook of 
patients with homozygous Type II 
hyperlipidaemia. 
Experience with portal diversion to treat 
patients with glycogen storage disease and 
hyperlipidaemia has also been accumulated in 
other centres with generally confirmatory 
results. If the desired corrections are not 
realized, thrombosis of the portacaval shunt 
must be suspected. 
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